articleThe LancetOct 2, 2014Closed access

Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial

FJFrederick J. RaalNHNarimon HonarpourDBDirk BlomGKG. Kees HovinghFXFeng Xu

University of the Witwatersrand · Amgen (United States) · +3 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

725
total citations
FWCI
89.90
Percentile
100%
References
31
Citations per year

Authors

8

Topics & keywords

Topics
Keywords
  • Evolocumab
  • PCSK9
  • Medicine
  • Placebo
  • Alirocumab
  • Internal medicine
  • Clinical endpoint
  • Familial hypercholesterolemia
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding